Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A first in human study of alpha-synuclein-PET tracers for Parkinson's disease

Trial Profile

A first in human study of alpha-synuclein-PET tracers for Parkinson's disease

Planning
Phase of Trial: Phase I

Latest Information Update: 15 Nov 2018

At a glance

  • Drugs Alpha-synuclein-PET tracers (Primary)
  • Indications Parkinson's disease
  • Focus Adverse reactions; First in man
  • Most Recent Events

    • 15 Nov 2018 According to an AC Immune media release, the company has been awarded a follow-up grant from The Michael J. Fox Foundation to facilitate the execution of this trial. The study will commence in Q1 of 2019.
    • 02 May 2018 According to an AC Immune media release, data were presented at he AAT-AD/PD Focus Meeting 2018 on March 15, 2018.
    • 21 Mar 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top